Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it will present the final results for the phase 1 clinical trial of ACE-011, its novel anabolic therapy for the treatment of bone loss at The American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting to be held in Honolulu, Hawaii, USA, September 16 – 19, 2007. The oral presentation is titled, “A Single Dose of ACE-011 Is Associated with Increases in Bone Formation and Decreases in Bone Resorption Markers in Healthy, Postmenopausal Women”, and will be presented on Tuesday September 18, 2007 at 11:15-11:30 a.m. in Kalakaua Ballroom AB, Hawaii Convention Center. This presentation represents the first time clinical data for an activin antagonist, a novel mechanism for an anabolic bone agent, will be presented at a scientific meeting.